Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01373151
First received: June 13, 2011
Last updated: November 19, 2014
Last verified: November 2014
  Purpose

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.


Condition Intervention Phase
Rheumatoid Arthritis
Drug: BMS-945429 Placebo
Biological: BMS-945429
Drug: Methotrexate
Drug: Methotrexate Placebo
Drug: Adalimumab Placebo
Drug: Adalimumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Proportion of subjects achieving an American College of Rheumatology (ACR) 20 response rate [ Time Frame: At 12 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects with ACR 20 response [ Time Frame: At weeks 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects achieving ACR 50 response rate [ Time Frame: At weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects achieving ACR 70 response rate [ Time Frame: At weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in disease activity as measured by Disease Activity Score 28 C-reactive protein (DAS28-CRP) [ Time Frame: Baseline (Day 1), To weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects with remission by DAS28-CRP [ Time Frame: At weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in Clinical Disease Activity Index (CDAI) [ Time Frame: Baseline (Day 1), To weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects with remission by CDAI [ Time Frame: At weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in Simplified Disease Activity Index (SDAI) [ Time Frame: Baseline (Day 1), To weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects with remission by SDAI [ Time Frame: At weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects with remission rate by Boolean definition [ Time Frame: At weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in Health Assessment Questionnaire (HAQ) disability Index [ Time Frame: Baseline (Day 1), To weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in Short Form 36 (SF-36) as measured by physical and mental components as well as 8 individual domain scores [ Time Frame: Baseline (Day 1), To weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in fatigue severity (VAS) [ Time Frame: Baseline (Day 1), To weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) as measured by 4 domain scores [ Time Frame: Baseline (Day 1), To weeks 12 and 24 ] [ Designated as safety issue: No ]
  • Mean change from baseline in radiographic progression of synovitis, osteitis (bone marrow edema), bone erosion and cartilage loss (joint-space narrowing) (MRI) [ Time Frame: Baseline (Day 1) and To weeks 12 ] [ Designated as safety issue: No ]
  • Mean change from baseline in radiographic progression of joint damage as measured by modified Sharp/van der Heijide scores (X-ray) [ Time Frame: Baseline (Day 1) and To weeks 24 ] [ Designated as safety issue: No ]
  • Safety will be measured by adverse events, clinically significant changes in vital signs, physical exams and ECG, laboratory test abnormality and immunogenicity changes from baseline [ Time Frame: Upto double-blind period (48 weeks) ] [ Designated as safety issue: Yes ]

Enrollment: 418
Study Start Date: June 2011
Estimated Study Completion Date: August 2020
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Arm 1
BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
Drug: BMS-945429 Placebo
Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
Biological: BMS-945429
Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
Drug: Methotrexate
Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
Drug: Adalimumab Placebo
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Experimental: Arm 2
BMS-945429 + Methotrexate + Adalimumab Placebo
Biological: BMS-945429
Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
Drug: Methotrexate
Tablets, Oral, 15 mg, Weekly, 48 weeks
Drug: Adalimumab Placebo
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Experimental: Arm 3
BMS-945429 + Methotrexate + Adalimumab Placebo
Biological: BMS-945429
Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
Drug: Methotrexate
Tablets, Oral, 15 mg, Weekly, 48 weeks
Drug: Adalimumab Placebo
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Experimental: Arm 4
BMS-945429 + Methotrexate + Adalimumab Placebo
Biological: BMS-945429
Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
Biological: BMS-945429
Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
Drug: Methotrexate
Tablets, Oral, 15 mg, Weekly, 48 weeks
Drug: Adalimumab Placebo
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Experimental: Arm 5
BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
Biological: BMS-945429
Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
Drug: Methotrexate Placebo
Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
Drug: Methotrexate
Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
Drug: Adalimumab Placebo
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Experimental: Arm 6
BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
Biological: BMS-945429
Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
Drug: Methotrexate Placebo
Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
Drug: Methotrexate
Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
Drug: Adalimumab Placebo
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Active Comparator: Arm 7
Adalimumab + Methotrexate
Drug: Methotrexate
Tablets, Oral, 15 mg, Weekly, 48 weeks
Drug: Adalimumab
Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Inadequate response to Methotrexate
  • Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization
  • American College of Rheumatology (ACR) global function status class 1-3
  • Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist
  • High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL

Exclusion Criteria:

  • Previously received or currently receiving concomitant biologic therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01373151

  Hide Study Locations
Locations
United States, Arizona
Sun Valley Arthritis Center, Ltd.
Peoria, Arizona, United States, 85381
United States, California
San Diego Arthritis Medical Clinic
San Diego, California, United States, 92108
United States, Connecticut
New England Research Associates, Llc
Trumbull, Connecticut, United States, 06611
United States, Illinois
Quincy Medical Group
Quincy, Illinois, United States, 62301
Rockford Orthopedic Associates, Llc.
Rockford, Illinois, United States, 61107
United States, Massachusetts
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States, 01605
United States, Mississippi
Arthritis Associates Of Mississippi
Jackson, Mississippi, United States, 39202
United States, Nebraska
Physician Research Collaboration, Llc
Lincoln, Nebraska, United States, 68516
United States, North Carolina
Box Arthritis And Rheumatology Of The Carolinas, Pllc
Charlotte, North Carolina, United States, 28210
United States, Oklahoma
Health Research Of Oklahoma
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
East Penn Rheumatology Associates, P.C.
Bethlehem, Pennsylvania, United States, 18015
Altoona Center For Clinical Research
Duncansville, Pennsylvania, United States, 16635
United States, Washington
Seattle Rheumatology Associates
Seattle, Washington, United States, 98104
Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina, 1425
Local Institution
Capital Federal, Buenos Aires, Argentina, 1428
Local Institution
Capital Federal, Buenos Aires, Argentina, 1431
Local Institution
Capital Federal, Buenos Aires, Argentina, 1015
Local Institution
Rosario, Santa Fe, Argentina, 2000
Local Institution
San Miguel De Tucuman, Tucuman, Argentina, 4000
Local Institution
Cordoba, Argentina, 5000
Local Institution
San Juan, Argentina, 5400
Belgium
Local Institution
Bruxelles, Belgium, 1200
Local Institution
Hasselt, Belgium, 3500
Brazil
Local Institution
Goiania, Goias, Brazil, 74110
Local Institution
Juiz De Fora, Minas Gerais, Brazil, 36010
Local Institution
Curitiba, Parana, Brazil, 80440
Local Institution
Curitiba, Parana, Brazil, 80060
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 91610
Local Institution
Sao Paulo, Brazil, 04032
Local Institution
Sao Paulo, Brazil, 04266
Canada, Quebec
Local Institution
Montreal, Quebec, Canada, H2L 1S6
Centre De Recherche Musculo-Squelettique
Trois-rivieres, Quebec, Canada, G8Z 1Y2
Canada
Local Institution
Quebec, Canada, G1W 4R4
Czech Republic
Local Institution
Praha 2, Czech Republic, 128 50
Local Institution
Praha 4, Czech Republic, 140 59
France
Local Institution
Bordeaux Cedex, France, 33076
Local Institution
Chambray Les Tours, France, 37170
Local Institution
Strasbourg Cedex, France, 67098
Germany
Local Institution
Berlin, Germany, 14059
Local Institution
Koeln, Germany, 50931
Local Institution
Leipzig, Germany, 04103
Local Institution
Wuerzburg, Germany, 97080
Hungary
Local Institution
Budapest, Hungary, 1027
Local Institution
Debrecen, Hungary, 4012
Local Institution
Gyula, Hungary, 5700
Local Institution
Veszprem, Hungary, 8200
Italy
Local Institution
Napoli, Italy, 80131
Local Institution
Padova, Italy, 35128
Local Institution
Reggio Emilia, Italy, 42100
Japan
Local Institution
Chiba-shi, Chiba, Japan, 2608712
Local Institution
Kitakyushu-shi, Fukuoka, Japan, 8078555
Local Institution
Higashi-hiroshima-shi, Hiroshima, Japan, 7390002
Local Institution
Kato-shi, Hyogo, Japan, 6731462
Local Institution
Miyazaki-shi, Miyazaki, Japan, 8800122
Local Institution
Nagano-shi, Nagano, Japan, 3808582
Local Institution
Nagasaki-shi, Nagasaki, Japan, 8528501
Local Institution
Sasebo-shi, Nagasaki, Japan, 8571165
Local Institution
Tomigusuku-shi, Okinawa, Japan, 9010243
Local Institution
Osaka-shi, Osaka, Japan, 5458586
Local Institution
Shizuoka-shi, Shizuoka, Japan, 4208623
Local Institution
Bunkyo-ku, Tokyo, Japan, 1138519
Local Institution
Shinjuuku-ku, Tokyo, Japan, 1608582
Local Institution
Toshima-ku, Tokyo, Japan, 1708476
Korea, Republic of
Local Institution
Daegu, Korea, Republic of, 705-718
Local Institution
Seoul, Korea, Republic of, 137-701
Local Institution
Seoul, Korea, Republic of, 133-792
Mexico
Local Institution
Mexico City, Distrito Federal, Mexico, 11850
Local Institution
Guadalajara, Jalisco, Mexico, 45040
Local Institution
Guadalajara, Jalisco, Mexico, 42650
Local Institution
Morelia, Michioacan, Mexico, 58270
Local Institution
Monterrey, Nuevo Leon, Mexico, 64020
Local Institution
Culiacan, Sinaloa, Mexico, 80230
Local Institution
San Luis Potosi, Mexico, 78213
Netherlands
Local Institution
Amsterdam, Netherlands, 1056 AB
Poland
Local Institution
Katowice, Poland, 40-748
Local Institution
Krakow, Poland, 31-531
Local Institution
Poznan, Poland, 60773
Local Institution
Warszawa, Poland, 02-118
Local Institution
Warszawa, Poland, 01-868
Russian Federation
Local Institution
Ekaterinburg, Russian Federation, 620102
Local Institution
Kazan, Russian Federation, 420064
Local Institution
Moscow, Russian Federation, 115522
Local Institution
Novosibirsk, Russian Federation, 630005
Local Institution
St. Petersburg, Russian Federation, 191014
Local Institution
Yaroslavl, Russian Federation, 150003
South Africa
Local Institution
Pretoria, Gauteng, South Africa, 0132
Local Institution
Pretoria, Gauteng, South Africa, 0083
Local Institution
Durban, Kwa Zulu Natal, South Africa, 4001
Local Institution
Panorama, Western Cape, South Africa, 7500
Local Institution
Pinelands, Cape Town, Western Cape, South Africa, 7405
Local Institution
Tygerberg, Western Cape, South Africa, 7505
Spain
Local Institution
A Coruna, Spain, 15006
Local Institution
Madrid, Spain, 28040
Local Institution
Santander, Spain, 39008
Local Institution
Santiago De Compostela, Spain, 15706
Local Institution
Sevilla, Spain, 41071
Taiwan
Local Institution
Changhua, Taiwan, 500
Local Institution
Kaohsiung, Taiwan, 833
Local Institution
Taichung, Taiwan, 404
Local Institution
Taoyuan, Taiwan, 333
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01373151     History of Changes
Other Study ID Numbers: IM133-001, 2010-023956-99
Study First Received: June 13, 2011
Last Updated: November 19, 2014
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration
Korea: Food and Drug Administration
Taiwan: Department of Health
Taiwan: National Bureau of Controlled Drugs
Canada: Health Canada
Hungary: National Institute of Pharmacy
Russia: Ethics Committee
Russia: FSI Scientific Center of Expertise of Medical Application
Germany: Federal Institute for Drugs and Medical Devices
Germany: Federal Office for Radiation Protection
Germany: Ministry of Health
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
South Africa: Medicines Control Council
Spain: Spanish Agency of Medicines
Japan: Ministry of Health, Labor and Welfare
Japan: Pharmaceuticals and Medical Devices Agency
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Brazil: Ethics Committee
Brazil: National Health Surveillance Agency
Chile: Instituto de Salud Pública de Chile
Peru: Instituto Nacional de Salud
Mexico: Federal Commission for Sanitary Risks Protection
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Italy: Ministry of Health
Italy: National Bioethics Committee
Italy: National Institute of Health
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Italy: The Italian Medicines Agency

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Adalimumab
Methotrexate
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Anti-Inflammatory Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014